Tetracycline (TC) is a well-known broad spectrum antibiotic, which is effective against many Gram positive and Gram negative bacteria. Controlled release nanoparticle formulations of TC have been reported, and could be beneficial for application in the treatment of periodontitis and dental bone infections. Furthermore, TC-controlled transcriptional regulation systems (Tet-on and Tet-off) are useful for controlling transgene expression in vitro and in vivo for biomedical research purposes; controlled TC release systems could be useful here, as well. Mesoporous silica nanomaterials (MSNs) are widely studied for drug delivery applications; Mobile crystalline material 41 (MCM-41), a type of MSN, has a mesoporous structure with pores forming channels in a hexagonal fashion. We prepared 41 ± 4 and 406 ± 55 nm MCM-41 mesoporous silica nanoparticles and loaded TC for controlled dug release; TC content in the TC-MCM-41 nanoparticles was 18.7% and 17.7% w/w, respectively. Release of TC from TC-MCM-41 nanoparticles was then measured in phosphate-buffered saline (PBS), pH 7.2, at 37 °C over a period of 5 h. Most antibiotic was released from both over this observation period; however, the majority of TC was released over the first hour. Efficacy of the TC-MCM-41 nanoparticles was then shown to be superior to free TC against Escherichia coli (E. coli) in culture over a 24 h period, while blank nanoparticles had no effect.
Mesoporous silica nanoparticles (MSNs) have been widely explored as drug delivery vehicles in cell and animal studies. To move this nanoparticle platform into the clinic, however, further work needs to be done to predict and assess potential adverse reactions and side-effects to optimize for their efficacious and safe use in patients. Toxicity may be dependent on a number of characteristics, including the size, shape, surface chemistry, and charge of MSNs. Thus, altering various physical and chemical properties of MSNs, while controlling for others, should reveal important parameters necessary for biocompatibility. In this work, reports on biocompatibility of MSNs in recent years have been reviewed and the effects of size, shape, surface chemistry, and porosity highlighted. Advances in triggered release of the drug from MSN delivery systems are also discussed. This article brings together current research on MSN biocompatibility and emphasizes the need for standardized characterization of MSNs, predictive cell studies, and harmonization of animal studies by investigators in the field, to move these sophisticated nanodevices from bench to bedside.
1 December 2021 in Journal of Pharmaceutical Sciences